Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;15(2):123-133.
doi: 10.1111/crj.13294. Epub 2020 Nov 5.

The airway microbiome in COPD, bronchiectasis and bronchiectasis-COPD overlap

Pei Yee Tiew  1   2 , Tavleen K Jaggi  1 , Louisa L Y Chan  1 , Sanjay H Chotirmall  1
Affiliations
Review

The airway microbiome in COPD, bronchiectasis and bronchiectasis-COPD overlap

Pei Yee Tiew et al. Clin Respir J. 2021 Feb.

Abstract

Objective: To review the airway microbiome in chronic obstructive pulmonary disease (COPD), bronchiectasis and bronchiectasis-COPD overlap (BCO).

Data source and study selection: Relevant studies were selected from PubMed, Google scholar, EMBASE and Web of Science. All studies involving human microbiomes, published in the English language, and using the search terms "COPD", "Chronic Obstructive Pulmonary Disease", "Bronchiectasis", "BCO" or "Bronchiectasis and COPD overlap", AND "microbiome", "mycobiome" or "metagenomics" were included.

Results: Despite variability in sampling methods and specimen types used, microbiome composition remains relatively comparable in COPD and bronchiectasis with prominence of Proteobacteria, Firmicutes and Bacteroidetes. Alterations to airway microbiomes occur in association to disease severity and/or exacerbations in COPD and bronchiectasis. Decreased alpha diversity and Haemophilus-predominant microbiomes are associated with poorer survival in COPD, while, in bronchiectasis, Pseudomonas-predominant microbiomes demonstrate high exacerbation frequency and greater symptom burden while Aspergillus-dominant mycobiome profiles associate with exacerbations. The role of the microbiome in BCO remains understudied.

Conclusion: Use of next-generation sequencing has revolutionised our detection and understanding of the airway microbiome in chronic respiratory diseases such as COPD and bronchiectasis. Targeted amplicon sequencing reveals important associations between the respiratory microbiome and disease outcome while metagenomics may elucidate functional pathways. How best to apply this information into patient care, monitoring and treatment, however, remains challenging and necessitates further study.

Keywords: BCO; COPD; bronchiectasis; metagenomics; microbiome; overlap.

PubMed Disclaimer

References

REFERENCES

    1. Chotirmall SH, Gellatly SL, Budden KF, et al. Microbiomes in respiratory health and disease: an Asia-Pacific perspective. Respirology. 2017;22(2):240-250.
    1. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One. 2010;5(1):e8578.
    1. Tiew PY, Mac Aogain M, Ali NABM, et al. The mycobiome in health and disease: emerging concepts, methodologies and challenges. Mycopathologia. 2020;185(2):207-231.
    1. Budden KF, Shukla SD, Rehman SF, et al. Functional effects of the microbiota in chronic respiratory disease. Lancet Respir Med. 2019;7(10):907-920.
    1. Cabrera-Rubio R, Garcia-Nunez M, Seto L, et al. Microbiome diversity in the bronchial tracts of patients with chronic obstructive pulmonary disease. J Clin Microbiol. 2012;50(11):3562-3568.

LinkOut - more resources